drugset / Trial / NCT01297192

A Clinical Study to Assess the Effect on Pharmacokinetics of Dosing Mirabegron (YM178) and Solifenacin Simultaneously

NCT01297192

Phase 1 Completed 41 enrolled Astellas Pharma Inc
Non-randomizedParallel-groupOpen-labelBasic science

Summary

This study investigates whether mirabegron (YM178) has an effect on the pharmacokinetics of solifenacin and whether solifenacin has an effect on the pharmacokinetics of mirabegron.

Timeline

Start
2009-03
Primary completion
2009-07
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Mirabegron Other / unclassified Oral
Subject Solifenacin Small molecule Oral

Indications

No indication recorded.